Evidence map›Paper›PMID 32310964›Full record

SynthesisPLoS computational biology2020

Methodological challenges in translational drug response modeling in cancer: A systematic analysis with FORESEE.

Lisa-Katrin Schätzle, Ali Hadizadeh Esfahani, Andreas Schuppert

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in PLoS computational biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Lisa-Katrin SchätzleJoint Research Center for Computational Biomedicine, RWTH Aachen University, Aachen, Germany.ORCID 0000-0002-4431-6360
Ali Hadizadeh EsfahaniJoint Research Center for Computational Biomedicine, RWTH Aachen University, Aachen, Germany.ORCID 0000-0003-0027-4813
Andreas SchuppertJoint Research Center for Computational Biomedicine, RWTH Aachen University, Aachen, Germany.ORCID 0000-0003-3783-6605
Institute for Advanced Study · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Translational models directly relating drug response specific processes that can be observed in vitro to their in vivo role in cancer patients constitute a crucial part of the development of personalized medication. Unfortunately, current studies often focus on the optimization of isolated model characteristics instead of examining the overall modeling workflow and the interplay of the individual model components. Moreover, they are often limited to specific data sets only. Therefore, they are often confined by the irreproducibility of the results and the non-transferability of the approaches into other contexts. In this study, we present a thorough investigation of translational models and their ability to predict the drug responses of cancer patients originating from diverse data sets using the R-package FORESEE. By systematically scanning the modeling space for optimal combinations of different model settings, we can determine models of extremely high predictivity and work out a few modeling guidelines that promote simplicity. Yet, we identify noise within the data, sample size effects, and drug unspecificity as factors that deteriorate the models' robustness. Moreover, we show that cell line models of high accuracy do not necessarily excel in predicting drug response processes in patients. We therefore hope to motivate future research to consider in vivo aspects more carefully to ultimately generate deeper insights into applicable precision medicine.

Indexed as

Antineoplastic AgentsDrug DesignComputational BiologyDatabases, GeneticGene Expression ProfilingHumansNeoplasmsTranscriptomeAntineoplastic Agents

Identifiers

PMID32310964
PMCPMC7192505
OpenAlexW3016665862

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.